Idorsia will host a live investor Q&A webcast and conference call following the publication of the OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the endothelin pathway – fits into the treatment landscape for difficult-to-control hypertension.
Date: Monday, September 8, 2025
Time: 16:00 CEST / 15:00 BST / 10:00 EDT
The call will start with a short presentation by senior management followed by a Q&A session.
Live Webcast (audio + slides):
The live webcast can be accessed from the Idorsia website https://www.idorsia.com/investors/news-and-events/investor-webcasts/aprocitentan-live-qa.
Dial-in procedure for analysts (audio only):
Members of the investment community who wish to ask questions are required to register in advance of the conference using the following link:
https://register-conf.media-server.com/register/BIea30fa533efa48b880d7dc1852237e1a
Replay: A replay of the investor webcast will be available approximately 60 minutes after the call has ended.
Attachment